Advertisement

International Journal of Hematology

, Volume 108, Issue 2, pp 123–129 | Cite as

Response to cyclosporine A and corticosteroids in adult patients with acquired pure red cell aplasia: serial experience at a single center

  • Xuemei Wu
  • Suli Wang
  • Xingyu Lu
  • Wenyi Shen
  • Chun Qiao
  • Yujie Wu
  • Ruinan Lu
  • Shuai Wang
  • Jianfu Zhang
  • Ming Hong
  • Yu Zhu
  • Jianyong Li
  • Guangsheng He
Original Article
  • 122 Downloads

Abstract

To assess response to cyclosporine A, and/or corticosteroids, and possible factors influencing the response in adult patients with acquired pure red cell aplasia (PRCA). Clinical data from 42 cases were retrospectively analyzed. These patients received cyclosporine A (CsA), and/or corticosteroids (CS), or other immunosuppressive agents on becoming refractory and relapse. Thirty-nine patients were evaluated. Remission induction therapy included CsA (n = 16), CS (n = 13), CsA in combination with CS (n = 6), or other immunosuppressive agents (n = 4). Initial response rates were 75.0, 46.2, 66.7 and 75.0%, respectively (P = 0.456). Cumulative response rates in patients who received CsA, CS, CsA in combination with CS, or other immunosuppressive agents were 69.6% (16/23), 50.0% (7/14), 71.4% (5/7), 42.9% (6/14), respectively (P = 0.376). Cumulative rates of CR were 26.1% (6/23), 28.6% (4/14), 57.1% (4/7), 14.3% (2/14), respectively (P = 0.284). In 27 refractory and relapsed PRCA patients, 11 of 17 patients (64.7%) achieved remission by CsA and/or CS regimen, while three of ten patients (30.0%) responded to other immunosuppressive agents (P = 0.120). CsA and/or CS were effective in treating PRCA. For patients with relapse or refractory PRCA, there were no satisfactory treatments if CsA and/or CS failed or were not administered.

Keywords

Pure red cell aplasia Cyclosporine A Corticosteroids 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Dessypris EN, Lipton JM. Red cell aplasia. In: Wintrobe’s clinical hematology. 11th ed. Philadelphia: Lippincott Williams &Wilkins; 2004. p. 1421–1427.Google Scholar
  2. 2.
    Goldman L, Schafer AI. Aplastic anemia and related bone marrow failure states. In: Bagby GC, editor. Goldman’s cecil medicine. 24th ed. New York: Elsevier; 2011. p. 1083–90.Google Scholar
  3. 3.
    Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111:1010–122.CrossRefPubMedGoogle Scholar
  4. 4.
    Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142:505–14.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Marmont AM. Therapy of pure red cell aplasia. Semin Hematol. 1991;28:285–97.PubMedGoogle Scholar
  6. 6.
    Lacy MQ, Kurtin PJ, Tefferi A. Pure red cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood. 1996;87:3000–6.PubMedGoogle Scholar
  7. 7.
    Mamiya S, Itoh T, Miura AB. Acquired pure red cell aplasia in Japan. Eur J Haematol. 1997;59:199–205.CrossRefPubMedGoogle Scholar
  8. 8.
    Zecca M, Stefano P, Nobili B, Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001;97:3995–7.CrossRefPubMedGoogle Scholar
  9. 9.
    Ghazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocyticleukemia. Blood. 2002;99:1092–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Ru X, Liebman HA. Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol. 2003;123:278–81.CrossRefPubMedGoogle Scholar
  11. 11.
    Means RT Jr. Pure red cell aplasia. Blood. 2016;128:2504–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Sawada K, Hirokawa M, Fujishima N, Teramura M, Bessho M, Dan K, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. A nationwide cohort study in Japan for the PRCA Collaborative Study Group. Haematologica. 2007;92:1021–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Hirokawa M, Sawada K, Nakao S, Fujishima N, Nakao S, Urabe A, et al. Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia: a nationwide cohort study in Japan by the PRCA collaborative study group. Haematologica. 2008;93:27–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Dessypris EN. Pure red cell aplasia. Baltimore: Johns Hopkins University Press; 1988.Google Scholar
  15. 15.
    Charles RJ, Sabo KM, Kidd PG, Abkowitz JL. The pathophysiology of pure red cell aplasia: implications for therapy. Blood. 1996;87(11):4831–8.PubMedGoogle Scholar
  16. 16.
    Montane E, Ibanez L, Vidal X, Ballarin E, Puig R, Garcia N, et al. Epidemiology of aplastic anemia: a prospective multicenter study. Haematologica. 2008;93:518–23.CrossRefPubMedGoogle Scholar
  17. 17.
    Kawahara S, Sasaki M, Isobe Y, Ando J, Noguchi M, Koike M, et al. Clinical analysis of 52 patients with granular lymphocyte proliferative disorder (GLPD) showed frequent anemia in indolent T-cell GLPD in Japan. Eur J Haematol. 2009;82:308–14.CrossRefPubMedGoogle Scholar
  18. 18.
    Kwong YL, Au WY, Leung AY, Tse EW. T-cell large granu1ar lymphocyte leukemia: an Asian perspective. Ann Hematol. 2010;89(4):331–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Burks EJ, Loughran TP Jr. Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome. Blood Rev. 2006;20:245–66.CrossRefPubMedGoogle Scholar
  20. 20.
    Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist. 2006;11(3):263–73.CrossRefPubMedGoogle Scholar
  21. 21.
    Qiu ZY, Fan L, Wang L, Qiao C, Wu YJ, Zhou JF, et al. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia with pure red cell aplasia. J Hematol Oncol. 2013;6:82.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kawano N, Nagahiro Y, Yoshida S, Yamashita K, Himeji D, Uezono S, et al. Clinical characteristics and outcomes of 11 patients with pure red cell aplasia at a single institution over a 13-year period. Intern Med. 2013;52:2025–30.CrossRefPubMedGoogle Scholar
  23. 23.
    Fujishima N, Sawada K, Hirokawa M, Oshimi K, Sugimoto K, Matsuda A, et al. Long-term responses and outcomes following immunosuppressive therapy in large granular lymphocyte leukemia-associated pure red cell aplasia: a Nationwide Cohort Study in Japan for the PRCA Collaborative Study Group. Haematologica. 2008;93:1555–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Hirokawa M, Sawada K, Fujishima N, Teramura M, Bessho M, Dan K, et al. Long-term outcome of patients with acquired chronic pure red cell aplasia (PRCA) following immunosuppressive therapy: a final report of the nationwide cohort study in 2004/2006 by the Japan PRCA collaborative study group. Br J Haematol. 2015;169:879–86.CrossRefPubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2018

Authors and Affiliations

  • Xuemei Wu
    • 1
  • Suli Wang
    • 1
  • Xingyu Lu
    • 1
  • Wenyi Shen
    • 1
  • Chun Qiao
    • 1
  • Yujie Wu
    • 1
  • Ruinan Lu
    • 1
  • Shuai Wang
    • 1
  • Jianfu Zhang
    • 1
  • Ming Hong
    • 1
  • Yu Zhu
    • 1
  • Jianyong Li
    • 1
  • Guangsheng He
    • 1
  1. 1.Department of Hematology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Hematology of Nanjing Medical University, Collaborative Innovation Center for Cancer Personalized MedicineNanjing Medical UniversityNanjingChina

Personalised recommendations